SRPT Related Analyst Ratings

May 13, 2013 12:28 PM Big Potential, Yet Hurdles Remain for Sarepta Therapeutic (SRPT) - Burrill

Apr 22, 2013 08:10 AM Needham & Company Starts Sarepta Therapeutic (SRPT) at Buy

Apr 16, 2013 07:08 AM Leerink Swann Downgrades Sarepta Therapeutic (SRPT) to Market Perform on Lack of FDA Clarity

Apr 16, 2013 07:05 AM Janney Montgomery Scott Downgrades Sarepta Therapeutic (SRPT) to Neutral

Apr 15, 2013 01:06 PM Wedbush Sees Sarepta Therapeutics (SRPT) Filing for Accelerated Approval of Eteplirsen

Apr 9, 2013 05:34 PM Study Helps Validates Sarepta Therapeutic's (SRPT) Technology

Apr 9, 2013 07:07 AM Canaccord Genuity Starts Sarepta Therapeutic (SRPT) at Buy

Apr 3, 2013 04:29 PM Baird Starts Sarepta Therapeutic (SRPT) at Outperform

Mar 20, 2013 07:49 AM William Blair Starts Sarepta Therapeutic (SRPT) at Outperform

Mar 19, 2013 08:02 AM Deutsche Bank Starts Sarepta Therapeutic (SRPT) at Buy; Could Be Worth Up to $71/Sh

Mar 5, 2013 06:56 AM Leerink Swann Starts Sarepta Therapeutic (SRPT) at Outperform, $45 PT

Jan 25, 2013 08:08 AM Cowen Starts Sarepta Therapeutic (SRPT) at Outperform

Nov 27, 2012 09:14 AM Dawson James Starts Sarepta Therapeutic (SRPT) at Market Outperform

Nov 26, 2012 02:54 PM Burrill Starts Sarepta (SRPT) at Market Outperform; Sees Plenty of Upside in DMD Space

Nov 26, 2012 09:56 AM Burrill Starts Sarepta Therapeutic (SRPT) at Market Outperform

Nov 21, 2012 09:18 AM Sarepta Therapeutics (SRPT) Jumps on Bullish Comments

Oct 4, 2012 03:50 PM Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year

Oct 3, 2012 07:58 AM Sarepta Therapeutic (SRPT) Could Be Worth $83-$139/Sh - Analyst

Sep 12, 2012 09:36 AM WBB Securities Downgrades Sarepta Therapeutic (SRPT) to Sell

Aug 27, 2012 08:42 AM ThinkEquity Starts Sarepta Therapeutic (SRPT) at Buy

Aug 9, 2012 09:57 AM WBB Securities Downgrades Sarepta Therapeutic (SRPT) to Hold

Jul 24, 2012 01:44 PM Sarepta Therapeutic (SRPT) Has Another Nearly 200% Upside - Analyst